These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30867024)

  • 21. WITHDRAWN: Toxoplasma gondii virulence factor ROP18 inhibits the host NF-κB pathway by promoting p65 degradation.
    Du J; An R; Chen L; Shen Y; Chen Y; Cheng L; Jiang Z; Zhang A; Yu L; Chu D; Shen Y; Luo Q; Chen H; Wan L; Li M; Xu X; Shen J
    J Biol Chem; 2014 May; 289(18):12578-92. PubMed ID: 24648522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ROP18 and ROP5 alleles combinations are related with virulence of T. gondii isolates from Argentina.
    Bernstein M; Pardini L; Bello Pede Castro B; Unzaga JM; Venturini MC; Moré G
    Parasitol Int; 2021 Aug; 83():102328. PubMed ID: 33713809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein targets of thiazolidinone derivatives in Toxoplasma gondii and insights into their binding to ROP18.
    Molina D; Cossio-Pérez R; Rocha-Roa C; Pedraza L; Cortes E; Hernández A; Gómez-Marín JE
    BMC Genomics; 2018 Nov; 19(1):856. PubMed ID: 30497375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the virulence determination mechanisms in a local Toxoplasma strain (T.gHB1) isolated from central China.
    Zhang W; Li L; Xia N; Zhou Y; Fang R; He L; Hu M; Shen B; Zhao J
    Parasitol Res; 2016 Oct; 115(10):3807-15. PubMed ID: 27225000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Two Major
    Hernández-de-Los-Ríos A; Murillo-Leon M; Mantilla-Muriel LE; Arenas AF; Vargas-Montes M; Cardona N; de-la-Torre A; Sepúlveda-Arias JC; Gómez-Marín JE
    Front Cell Infect Microbiol; 2019; 9():413. PubMed ID: 31867288
    [No Abstract]   [Full Text] [Related]  

  • 27. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
    Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
    Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Toxoplasma gondii pseudokinase inhibits host IRG resistance proteins.
    Fleckenstein MC; Reese ML; Könen-Waisman S; Boothroyd JC; Howard JC; Steinfeldt T
    PLoS Biol; 2012; 10(7):e1001358. PubMed ID: 22802726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
    Zaka M; Abbasi BH; Durdagi S
    J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Hashizaki E; Sasai M; Okuzaki D; Nishi T; Kobayashi T; Iwanaga S; Yamamoto M
    mBio; 2023 Feb; 14(1):e0325622. PubMed ID: 36715543
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Subekti DT; Ekawasti F; Desem MI; Azmi Z
    J Vet Sci; 2021 Nov; 22(6):e88. PubMed ID: 34854270
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK; Ghate M; Goel A
    J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
    Mouhcine M; Kadil Y; Rahmoune I; Filali H
    Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasomal degradation of T. gondii ROP18 requires Derlin2.
    Tang Y; Zheng M; An R; Chen L; Gong L; Cai H; Liu K; Yu L; Shen J; Du J
    Acta Trop; 2017 Oct; 174():106-113. PubMed ID: 28669563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The polymorphic pseudokinase ROP5 controls virulence in Toxoplasma gondii by regulating the active kinase ROP18.
    Behnke MS; Fentress SJ; Mashayekhi M; Li LX; Taylor GA; Sibley LD
    PLoS Pathog; 2012; 8(11):e1002992. PubMed ID: 23144612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encephalitis is mediated by ROP18 of
    An R; Tang Y; Chen L; Cai H; Lai DH; Liu K; Wan L; Gong L; Yu L; Luo Q; Shen J; Lun ZR; Ayala FJ; Du J
    Proc Natl Acad Sci U S A; 2018 Jun; 115(23):E5344-E5352. PubMed ID: 29784816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.